- Home
- BLRX vs THAR Comparison
BLRX vs THAR Comparison
Compare BLRX & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- THAR
- Stock Information
- Founded
- BLRX 2003
- THAR 2017
- Country
- BLRX Israel
- THAR United States
- Employees
- BLRX N/A
- THAR N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- THAR Health Care
- Exchange
- BLRX Nasdaq
- THAR Nasdaq
- Market Cap
- BLRX 17.1M
- THAR 16.8M
- IPO Year
- BLRX 2011
- THAR 2022
- Fundamental
- Price
- BLRX N/A
- THAR $3.18
- Analyst Decision
- BLRX Strong Buy
- THAR Strong Buy
- Analyst Count
- BLRX 2
- THAR 1
- Target Price
- BLRX $19.00
- THAR $17.00
- AVG Volume (30 Days)
- BLRX 52.2K
- THAR 644.6K
- Earning Date
- BLRX 11-24-2025
- THAR 11-06-2025
- Dividend Yield
- BLRX N/A
- THAR N/A
- EPS Growth
- BLRX N/A
- THAR N/A
- EPS
- BLRX N/A
- THAR N/A
- Revenue
- BLRX $17,251,000.00
- THAR N/A
- Revenue This Year
- BLRX N/A
- THAR N/A
- Revenue Next Year
- BLRX N/A
- THAR N/A
- P/E Ratio
- BLRX N/A
- THAR N/A
- Revenue Growth
- BLRX 1.19
- THAR N/A
- 52 Week Low
- BLRX $2.30
- THAR $0.95
- 52 Week High
- BLRX $22.60
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- BLRX 69.50
- THAR 49.85
- Support Level
- BLRX $3.57
- THAR $2.88
- Resistance Level
- BLRX $4.56
- THAR $3.17
- Average True Range (ATR)
- BLRX 0.27
- THAR 0.31
- MACD
- BLRX 0.08
- THAR -0.00
- Stochastic Oscillator
- BLRX 87.13
- THAR 40.22
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.